NEUROCRINE BIOSCIENCES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NEUROCRINE BIOSCIENCES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $94.52M | Feb 13, 2018 |
| FY2017 | Sep 30, 2017 | $60.77M | Feb 13, 2018 |
| FY2017 | Jun 30, 2017 | $6.34M | Feb 13, 2018 |
| FY2017 | Mar 31, 2017 | $0 | Feb 13, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Feb 13, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Feb 13, 2018 |
| FY2017 | Jun 30, 2016 | $0 | Feb 13, 2018 |
| FY2017 | Mar 31, 2016 | $15.00M | Feb 13, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Feb 14, 2017 |
| FY2016 | Sep 30, 2015 | $0 | Feb 14, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.86B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.36B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.89B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.49B | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $1.13B | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $247.90M | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | $258.50M | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | $302.40M | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | $237.10M | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $244.10M | Feb 5, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $478.60M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $341.30M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $249.70M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $154.50M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $89.60M | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $347.90M | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | ($57.60M) | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | $79.60M | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | $37.40M | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $34.00M | Feb 5, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $619.10M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $570.50M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $250.90M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $249.00M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $102.50M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $163.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $72.30M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $36.80M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | ($131.36M) | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | ($147.37M) | Feb 8, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $160.52M | Feb 8, 2019 |
| FY2018 | Dec 31, 2017 | $121.83M | Feb 8, 2019 |
| FY2018 | Dec 31, 2016 | $94.29M | Feb 8, 2019 |
| FY2017 | Dec 31, 2015 | $81.49M | Feb 13, 2018 |
| FY2016 | Dec 31, 2014 | $46.43M | Feb 14, 2017 |
| FY2015 | Dec 31, 2013 | $39.25M | Feb 11, 2016 |
| FY2014 | Dec 31, 2012 | $37.16M | Feb 9, 2015 |
| FY2013 | Dec 31, 2011 | $30.95M | Feb 11, 2014 |
| FY2012 | Dec 31, 2010 | $31.15M | Feb 8, 2013 |
| FY2011 | Dec 31, 2009 | $33.72M | Feb 9, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.16B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $887.60M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $752.70M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $583.30M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $433.30M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $354.10M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $248.90M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $169.91M | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $68.08M | Feb 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $782.70M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $595.40M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $389.90M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $339.40M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $256.50M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $228.50M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $147.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $101.40M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | ($94.33M) | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | ($106.18M) | Feb 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $38.20M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $28.30M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $16.50M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $23.40M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $10.90M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $14.70M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $24.80M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $6.94M | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $4.11M | Feb 8, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.63B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $3.72B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $3.25B | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $2.37B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $2.07B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.73B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.31B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $993.15M | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $817.59M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $365.09M | Feb 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.38B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.13B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $1.02B | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $660.90M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $698.50M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $608.50M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $669.10M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $512.39M | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $445.45M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $50.21M | Feb 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.25B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.59B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $2.23B | Feb 11, 2026 |
| FY2025 | Dec 31, 2022 | $1.71B | Feb 11, 2026 |
| FY2024 | Dec 31, 2021 | $1.37B | Feb 10, 2025 |
| FY2023 | Dec 31, 2020 | $1.13B | Feb 9, 2024 |
| FY2022 | Dec 31, 2019 | $636.90M | Feb 9, 2023 |
| FY2021 | Dec 31, 2018 | $480.80M | Feb 11, 2022 |
| FY2020 | Dec 31, 2017 | $372.20M | Feb 5, 2021 |
| FY2019 | Dec 31, 2016 | $314.88M | Feb 7, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.70M | Feb 10, 2025 |
| FY2024 | Dec 31, 2023 | $5.80M | Feb 10, 2025 |
| FY2024 | Dec 31, 2022 | $5.40M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $0 | Feb 9, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $447.70M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $29.20M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($157.10M) | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | ($406.80M) | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | ($635.80M) | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | ($725.40M) | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | ($1.13B) | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | ($1.18B) | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | ($1.20B) | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | ($1.06B) | Feb 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $713.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $233.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $251.10M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $262.90M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $340.80M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $187.10M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $112.30M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $141.71M | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $254.71M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $83.27M | Feb 13, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | 3 | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 5, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | 3 | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 5, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 100.10M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 99.40M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | 98.70M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | 96.50M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | 94.90M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | 93.50M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | 92.30M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | 90.80M | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | 88.79M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | 86.88M | Feb 13, 2018 |